drugset / Trial / NCT00265655

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

NCT00265655

Phase 2 Completed 40 enrolled Agennix
NaSingle-groupOpen-labelTreatment

Summary

To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.

Timeline

Start
2005-11
Primary completion
2008-01
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Satraplatin Other / unclassified 80 mg/m2 Oral

Indications